Q-omics provides the consensus-scored ZNF75A profile across patient tissues and cancer cell-line models. ZNF75A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNF75A is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF75A RNA expression shows 20,648 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, THCA, and UVM as cancer lineages where ZNF75A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF75A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF75A survival associations across molecular data types. ZNF75A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF75A RNA expression–survival associations across cancer types. High ZNF75A expression shows unfavorable associations in KIRP, LGG, UVM and ACC, but favorable associations in HNSC and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNF75A RNA expression.
This table summarizes ZNF75A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF75A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF75A shows lower tumor expression in THCA, KICH and COAD and higher tumor expression in LIHC, BRCA and HNSC. The THCA box plot shows higher ZNF75A RNA expression in normal versus tumor tissue (log2 FC = −0.937, t-test p < 0.001).
This table shows molecular features associated with ZNF75A in patient tissues and cancer cell lines. In patient samples, ZNF75A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF75A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
